Skip to main content
Department of Neurology

Department of Neurology

Multiple Sclerosis



Multiple Sclerosis Clinic

UC Davis Medical Center
4860 Y Street, Suite 0100
Sacramento, CA 95817
(916) 734-3588



Our department’s faculty members provide care for patients with multiple sclerosis (MS). They also conduct both basic and clinical research aimed at developing new treatments.

Multiple Sclerosis Clinic

Dr. Richman with others

The Multiple Sclerosis Clinic evaluates and treats a large number of patients with multiple sclerosis and other neuroimmunological disorders.

The MS team comprises two neurologists or neuroimmunologists, an MS neurology fellow, an MS nurse, and a study coordinator. The team also includes additional study coordinators and research associates.

Clinical Trials

Our researchers have developed new drugs that have shown promise as future treatments for MS. Patients are able to participate in several clinical trials, which are designed to test these and other new therapies to manage MS. The studies that are currently enrolling at UC Davis are listed below.


Open Studies Currently Enrolling New Participants at UC Davis


A Multicenter, randomized, rater-and dose-blinded, study to compare the efficacy and safety of 0.25 mg and 0.5 mg of fingolimod with glatiramer acetate 20 mg s.c. in patients with RRMS

For more information, enter NCT01633112 into the search box at www.clinicaltrials.gov.


A Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS

For more information, enter NCT01803867into the search box at www.clinicaltrials.gov


A Phase 2/3 Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients

For more information, enter NCT01628393 into the search box at www.clinicaltrials.gov


A Phase 1 Randomized Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis

For more information, enter NCT01585766 into the search box at www.clinicaltrials.gov.


A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

For more information, enter NCT01665144 into the search box at www.clinicaltrials.gov.


If you are interested in participating or want more information on our current clinical trials, please contact:
Janelle Butters, RN, at (916) 734-6276 or by email:  Janelle.Butters@ucdmc.ucdavis.edu